Drugs / Gefarnate
Gefarnate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03610321 | Sep 2019 → Sep 2021 | coronary artery disorder | First Affiliated Hospital of Harbin Medical University | Unknown | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT01051388 Comparator | Aug 2008 → Jul 2010 | cardiovascular disorder | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | Completed | No outcome recorded |
| Phase 3 | NCT00762359 Comparator | May 2007 → Nov 2008 | duodenal ulcer, gastric ulcer | Takeda | Terminated | Met primary |
| Phase 3 | NCT00787254 Comparator | Apr 2007 → May 2009 | duodenal ulcer, gastric ulcer | Takeda | Completed | Met primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gefarnate | “Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 6 to 24 months.” NCT00787254 ↗ |
| Known as | DA 688 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105085 ↗ |
| Known as | Gefanil | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105085 ↗ |
| Known as | Gefarnate Tablets | “Gefarnate Tablets is a kind of anti-ulcer and gastritis treatment.” NCT03610321 ↗ |
| Known as | Gefarnato | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105085 ↗ |
| Modality | Small molecule | — CHEMBL2105085 ↗ |
| Route | Oral | “Gefarnate 50 mg, capsules, orally, twice daily” NCT00762359 ↗ |